Facebook
X

Phone: (843) 449-1010 | 823 82nd Parkway, Suite B, Myrtle Beach, SC 29572

Home
About Us
Staff
Current Trials
Patient Info
Testimonials
In The News
- In The News
Contact
Search
Menu Menu

Blog - Latest News

You are here: Home1 / Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide2 / Evaluation of clinically

Evaluation of clinically

October 29, 2019/0 Comments/by CURC

Share this entry

Share on Facebook
Share on X
Share on X
Share on WhatsApp
Share on Pinterest
Share on LinkedIn
Share on Tumblr
Share on Vk
Share on Reddit
Share by Mail

/wp-content/uploads/logo-1.png 0 0 CURC /wp-content/uploads/logo-1.png CURC2019-10-29 09:32:592019-10-29 09:32:59Evaluation of clinically

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Name *

Email *

Website

Comment *

Δ

Current Happenings

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy
ZERO Prostate Cancer Tee-Off
BCAN- Walk To End Bladder Cancer
Apalutamide for High-Risk Localized Prostate Cancer Following Radical Prostatectomy (Apa-RP)
Dr. Shore awarded the LUGPA Presidential Citation
The New England Journal of Medicine, 10/19/23
Influencing Best Practices for Genomic and Germline Testing in Urology – Abhishek Srivastava
Dr. Shore named 2023 Slotkin Lecturer for Outstanding Lecture

Archives

Archives

Contact

Carolina Urologic Research Center
823 82nd Parkway, Suite B
Myrtle Beach, SC 29572

Phone: (843) 839-1679
Fax: (843) 286-0119

Email:
info@curcmb.com

Recent Happenings

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy
ZERO Prostate Cancer Tee-Off
BCAN- Walk To End Bladder Cancer
Apalutamide for High-Risk Localized Prostate Cancer Following Radical Prostatectomy (Apa-RP)

Our Affiliates

©2024 Carolina Urologic Research Center, LLC | All Rights Reserved | Site Design by Studio303, Inc.

Facebook
X